Skip to main content
Updated:
Original:

5 Top Stock Gainers for Tuesday Climb After Powell Renomination

Investors were still reacting to President Joe Biden's decision to name Jerome Powell to a second term as Federal Reserve Chairman.

Stocks ended mixed Tuesday as investors reacted to President Joe Biden's decision to name Jerome Powell to a second term as Federal Reserve Chairman.

Here are some of the market's biggest gainers for Tuesday:

1. XPeng | Increase 8.3%

XPeng  (XPEV) - Get Xpeng Inc Report shares jumped after the China-based electric carmaker posted stronger-than-expected third-quarter revenues amid the global shortage in semiconductor supplies. Xpeng delivered 25,666 cars over the three months ending in October, the group said, a 200% increase from the same period last year.

2. Dollar Tree | Increase 9.2%

Shares of Dollar Tree  (DLTR) - Get Dollar Tree, Inc. Report were climbing after the discount variety store operator posted third-quarter earnings that were largely in-line with Wall Street forecasts. Revenue rose 3.9% to $6.42 billion, matching analysts' estimates of $6.41 billion. Same-store sales were up 1.6%.

TheStreet Recommends

3. Burlington Stores | Increase 8.6%

Burlington Stores  (BURL) - Get Burlington Stores, Inc. Report shares rose after the discount department store chain posted better-than-expected fiscal-third-quarter earnings. The company posted net income of $93 million, or $1.36 a share, compared with $103 million, or $1.53 a share, for the third quarter of 2019.

4. XL Fleet | Increase 6.7%

Shares of XL Fleet  (XL) - Get XL Fleet Corp. Class A Report surged after the electric vehicle tech company said it was awarded a contract by the Defense Innovation Unit and the U.S. Army’s Project Manager Transportation Systems to prototype a fuel-saving technology for military vehicles.

5. Pasithea Therapeutics | Increase 153%

Pasithea Therapeutics  (KTTA) - Get Pasithea Therapeutics Corp. Report shares skyrocketed after the biotech said that its subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray for treatment-resistant depression in adults, and has begun offering the treatment in its Knightsbridge, London location.